(Corrects syntax in paragraph 1)
(Reuters) – Pfizer Inc and its German partner BioNtech SE on Friday said they have requested U.S. regulatory agencies to expand the emergency use of their COVID-19 vaccine in adolescents aged 12 to 15.
In March, the drugmakers said the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year olds in a clinical trial.
The Pfizer/BioNTech two-shot vaccine is already authorized for use in people as young as 16.
(This story refiles to correct syntax in paragraph 1)
(Reporting by Mrinalika Roy in Bengaluru; Editing by Ramakrishnan M.)
